Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is

Simply Wall St03:10

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

PDF VersionNEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central

Axsome TherapeuticsJul 11 12:00

RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating

Axsome Therapeutics (AXSM) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $97 to $190.

MT NewswiresJul 9 20:07

Express News | Axsome Therapeutics Inc : RBC Raises Target Price to $131 From $130

BreakingsJul 9 19:35

Axsome Therapeutics' Auvelity Shows Strong Market Penetration and Sales Growth Potential

TipRanksJul 8 18:26

Mizhuo's Top Picks in Healthcare for July

Seeking AlphaJul 4 01:34